CK
NAVB

Carnick & Kubik’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Carnick & Kubik’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8
Closed -$342 – 369
2015
Q3 		$342 Buy
+8
New +$302 ﹤0.01% 407

Other funds holding NAVB

CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carnick & Kubik's NAVB Position: Q4 2015 in Review

Carnick & Kubik sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2015, closing a stake of 8 shares — an estimated $342 sold.

Carnick & Kubik first reported a position in NAVB in Q3 2015 and held it in 1 quarter. The position peaked at $342 in Q3 2015. 78 funds tracked by Wall St. Rank hold NAVB as of Q4 2015.

  • Carnick & Kubik reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
  • Carnick & Kubik sold 8 Navidea Biopharmaceuticals Inc. shares in Q4 2015, an estimated $342.
  • Carnick & Kubik first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2015 and held it in 1 quarter.
  • Carnick & Kubik's Navidea Biopharmaceuticals Inc. position peaked at $342 in Q3 2015.
  • 78 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2015.

Based on Carnick & Kubik's 13F filing for Q4 2015, filed 11 Feb 2016.